<DOC>
	<DOC>NCT01102335</DOC>
	<brief_summary>The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.</brief_summary>
	<brief_title>Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE) HBVDNA &gt; 10^3copies/mL, including alanine aminotransferase (ALT) normal patient expected survive time &gt; 1 year HBV marker positive (anyone of HbsAg, HbsAb, HbeAg, HbeAb and HbcAb) antiviral therapy history alanine aminotransferase (ALT) &gt;400 U/L serum total bilirubin &gt; 50 Î¼mol/L HBVDNA &gt; 10^9copies/mL extrahepatic metastasis or main portal vein embolus apparent cardiac or pulmonary dysfunction liver function: Child B or Child C HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>hepatitis B virus</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Drug Toxicity</keyword>
	<keyword>Survival</keyword>
</DOC>